Malignant vascular tumours of the pleura in "asbestos" workers and endothelial differentiation in malignant mesothelioma.
BACKGROUND
Three cases of diffuse malignant vascular tumours of the pleura are described which mimicked malignant mesothelioma clinically and pathologically (so called "pseudomesothelioma"). All had occupational histories of exposure to asbestos. The relationship of these tumours to mesothelioma and asbestos exposure is discussed.


METHODS
To examine the histogenetic relationship between mesothelioma and these three tumours an immunohistochemical analysis of vascular marker (CD31, CD34, and Von Willebrand factor) expression was undertaken in 92 cases of pleural mesothelioma, in addition to these three tumours. Electron microscopic fibre analysis of lung tissue was performed on each of the three cases to assess asbestos fibre content.


RESULTS
Diffuse pleural epithelioid haemangioendotheliomas may closely resemble malignant mesothelioma clinically and pathologically but, of the 92 pleural mesotheliomas tested, none showed expression of CD31, CD34, and Von Willebrand factor. Although all three cases had claimed exposure to asbestos, ferruginous bodies typical of asbestos were only seen by light microscopy in case 2, and only in this subject was the asbestos fibre content raised in comparison with the range seen in a non-exposed background population. The latent period in the pleural epithelioid haemangioendotheliomas ranged from 18 to 60 years.


CONCLUSIONS
Endothelial differentiation does not appear to occur in mesothelioma and therefore should be clearly separated from it. No definite association between pleural epithelioid haemangioendothelioma and exposure to asbestos can be made from this small series but further investigation is warranted.
Attanoos
R L
RL
Department of Histopathology, Llandough Hospital, Cardiff, UK.
Suvarna
S K
SK
Rhead
E
E
Stephens
M
M
Locke
T J
TJ
Sheppard
M N
MN
Pooley
F D
FD
Gibbs
A R
AR
D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D001194:Asbestos / Q000009:adverse effects*; D002273:Carcinogens / Q000009:adverse effects*; D003937:Diagnosis, Differential; D018323:Hemangioendothelioma, Epithelioid / Q000175:diagnosis* / Q000209:etiology; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000175:diagnosis* / Q000209:etiology; D008854:Microscopy, Electron / Q000379:methods; D008875:Middle Aged; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000032:analysis; D010997:Pleural Neoplasms / Q000175:diagnosis* / Q000209:etiology; D019043:Vascular Neoplasms / Q000175:diagnosis* / Q000209:etiology; D014841:von Willebrand Factor / Q000737:chemistry
D018952:Antigens, CD34; D002273:Carcinogens; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D014841:von Willebrand Factor; D001194:Asbestos